Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Real-time Estimate Cboe BZX  -  02:48 2022-10-03 pm EDT
9.800 USD   +2.40%
09/28Alx Oncology : Corporate Presentation
PU
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
GL
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/27/2022 09/28/2022 09/29/2022 09/30/2022 10/03/2022 Date
9.48(c) 9.94(c) 9.5(c) 9.57(c) 9.76 Last
200 386 118 644 115 810 163 564 85 554 Volume
-1.56% +4.85% -4.43% +0.74% +1.99% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -126 M - -
Net cash position 2022 247 M - -
P/E ratio 2022 -3,17x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -158 M - -
Net cash position 2023 215 M - -
P/E ratio 2023 -2,90x
Yield 2023 -
Capitalization 390 M 390 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 52
Free-Float 73,6%
More Financials
Company
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on helping patients fight cancer by developing a pipeline of product candidates based on protein engineering and oncology led by the cluster of differentiation 47 (CD47) blocker. It is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities... 
More about the company
Ratings of ALX Oncology Holdings Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about ALX ONCOLOGY HOLDINGS INC.
09/28Alx Oncology : Corporate Presentation
PU
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
GL
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
AQ
09/01ALX Oncology Announces Upcoming Investor Conference Participation
GL
08/26UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating
MT
08/16ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
MT
08/16ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
PR
08/15Alx Oncology : Corporate Presentation
PU
08/15ALX Oncology Says Evorpacept Selected in Early-Stage Trial in Combination With Enhertu ..
MT
08/15ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
GL
08/15ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative Announces the Sele..
CI
08/11First Patient Dosed in ALX Oncology's Mid-Stage Trial of Colorectal Cancer Combination ..
MT
08/11ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of E..
GL
08/11ALX Oncology Holdings Inc. Announces First Patient Dosed in Phase 2 Investigator-Sponso..
CI
08/09Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintain..
MT
More news
News in other languages on ALX ONCOLOGY HOLDINGS INC.
08/16L'Evorpacept d'ALX Oncology choisi comme nouveau bras de traitement dans un essai sur l..
08/15ALX Oncology déclare qu'Evorpacept a été sélectionné dans un essai de stade précoce en ..
08/15ALX Oncology Holdings Inc. et Quantum Leap Healthcare Collaborative annoncent la sélect..
08/11Le premier patient reçoit une dose dans le cadre de l'essai de mi-étape d'ALX Oncology ..
08/11ALX Oncology Holdings Inc. annonce l'administration d'une dose à un premier patient dan..
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
More recommendations
ETFs positioned on ALX ONCOLOGY HOLDINGS INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Virtus LifeSci Biotech Clinical Trials ETF - USD1.02%6.53%United_States
ALPS Medical Breakthroughs ETF - USD0.2%4.04%United_States
IQ Chaikin U.S. Small Cap ETF - USD0.14%-1.05%United_States
Invesco Nasdaq Biotechnology ETF - USD0.04%2.33%-United_States
IShares Micro-Cap ETF - USD0.04%-0.10%United_States
More ETFs positioned on ALX ONCOLOGY HOLDINGS INC.
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 9,57 $
Average target price 38,13 $
Spread / Average Target 298%
EPS Revisions
Managers and Directors
Jaume Pons President, Chief Executive Officer & Director
Peter S. García Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ALX ONCOLOGY HOLDINGS INC.-55.47%390
GILEAD SCIENCES, INC.-15.04%77 320
VERTEX PHARMACEUTICALS31.85%74 255
REGENERON PHARMACEUTICALS, INC.9.08%73 646
BIONTECH SE-47.68%32 778
WUXI APPTEC CO., LTD.-39.54%29 044